The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $80 from $54 and keeps a Buy rating on the shares. The ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Also Read: Takeda-Protagonist Therapeutics Partnered Investigational ... Academy of Dermatology Annual Meeting, show once daily icotrokinra demonstrated significant skin clearance and a favorable ...